Top

Published in:

01-06-2022 | Parkinson's Disease | Original Article

Mortality of Parkinson’s disease in Italy from 1980 to 2015

Authors: Monica Ulivelli, Daiana Bezzini, Lucia Kundisova, Ilaria Grazi, Mario Alberto Battaglia, Nicola Nante, Simone Rossi

Published in: Neurological Sciences | Issue 6/2022

Abstract

Objective

To evaluate mortality for Parkinson’s disease (PD) in Italy during a long time period (1980–2015) and to discuss the role of possible general and specific influencing factors.

Methods

Based on mortality data provided by the Italian National Institute of Statistics, sex- and age-specific crude mortality rates were computed, for the whole country and for its main geographical sub-areas. Rates were standardized using both direct (annual mortality rates AMRs) and indirect (standardized mortality rates SMRs) methods. SMRs were used to evaluate geographical differences, whereas AMRs and joinpoint linear regression analysis to study mortality trends.

Results

Considering the entire period, highest mortality rates were observed in males (AMR/100,000: 9.0 in males, 5.25 in females), in North-West and Central Italy (SMR > 100). Overall PD mortality decreased from mid-eighties onwards and then rapidly reversed the trend in the period 1998–2002, rising up to a maximum in 2015, with some differences according to sex and geographical areas.

Conclusions

Several factors may have contributed to the rapid inversion of decreasing trend in mortality observed in the last part of XX century. Possible explanations of this rising trend are related to the increasing burden of PD (especially in males and in certain Italian regions), caused by different factors as population aging, physiological prevalence rise due to incidence exceeding mortality, and growing exposure to environmental or occupational risk factors. In addition, the accuracy of death certificate compilation could account for geographical differences and for the temporal trend. The role of levodopa and recently introduced dopaminergic drugs is also discussed.

Moustafa AA, Chakravarthy S, Phillips JR et al (2016) Motor symptoms in Parkinson’s disease: a unified framework. Neurosci Biobehav Rev 68:727–740. https://doi.org/10.1016/j.neubiorev.2016.07.010CrossRefPubMed

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397(10291):2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-XCrossRefPubMed

Belvisi D, Pellicciari R, Fabbrini A et al (2020) Risk factors of Parkinson disease: simultaneous assessment, interactions, and etiologic subtypes. Neurology 95(18):e2500–e2508. https://doi.org/10.1212/WNL.0000000000010813CrossRefPubMedPubMedCentral

Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435–450. https://doi.org/10.1038/nrn.2017.62CrossRefPubMed

Aarsland D, Creese B, Politis M et al (2017) Cognitive decline in Parkinson disease. Nat Rev Neurol 13(4):217–231. https://doi.org/10.1038/nrneurol.2017.27CrossRefPubMedPubMedCentral

Solla P, Masala C, Pinna I et al (2021) Frequency and determinants of olfactory hallucinations in Parkinson’s disease patients. Brain Sci 11(7):841. https://doi.org/10.3390/brainsci11070841CrossRefPubMedPubMedCentral

Riccò M, Vezzosi L, Balzarini F, et al (2020) Prevalence of Parkinson disease in Italy: a systematic review and meta-analysis. Acta Biomed 7;91(3):e2020088. https://doi.org/10.23750/abm.v91i3.9443

Balestrino R, Schapira AHV (2020) Parkinson Disease. Eur J Neurol 27(1):27–42. https://doi.org/10.1111/ene.14108CrossRefPubMed

Istat. L’evoluzione della mortalità per causa: le prime 25 cause di morte. Anni 2003–2014. Istat report 2017 https://www.istat.it/it/files//2017/05/Report-cause-di-morte-2003-14.pdf. Accessed 30 Dec 2021

10.

De Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE (2020) Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. Lancet Neurol 19:452–461. https://doi.org/10.1016/S1474-4422(20)30036CrossRefPubMed

11.

Morgante L, Salemi G, Meneghini F et al (2000) Parkinson’s disease survival. A population-based study. Arch Neurol 57:507–512. https://doi.org/10.1001/archneur.57.4.507CrossRefPubMed

12.

EUROSTAT. Revision of the European standard population: report of the Eurostat’s task force. Luxembourg: EUROPEAN UNION 2013

13.

GBD (2016) Neurology Collaborators (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459–480. https://doi.org/10.1016/S1474-4422(18)30499-XCrossRef

14.

Deuschl G, Beghi E, Fazekas F et al (2020) The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health 5(10):e551–e567. https://doi.org/10.1016/S2468-2667(20)30190-0CrossRefPubMed

15.

Rong S, Xu G, Liu B et al (2021) Trends in mortality from Parkinson disease in the United States, 1999–2019. Neurology 97(20):e1986–e1993. https://doi.org/10.1212/WNL.0000000000012826CrossRefPubMed

16.

Poortvliet PC, Gluch A, Silburn PA, Mellick GD (2021) The Queensland Parkinson’s Project: an overview of 20 years of mortality from Parkinson’s disease. J Mov Disord 14(1):34–41. https://doi.org/10.14802/jmd.20034CrossRefPubMed

17.

Wahl D, Solon-Biet SM, Cogger VC et al (2019) Aging, lifestyle and dementia. Neurobiol Dis 130:104481. https://doi.org/10.1016/j.nbd.2019.104481CrossRefPubMed

18.

Bezzini D, Ulivelli M, Gualdani E et al (2020) Increasing prevalence of multiple sclerosis in Tuscany. Italy Neurol Sci 41(2):397–402. https://doi.org/10.1007/s10072-019-04090-0CrossRefPubMed

19.

Battaglia MA, Bezzini D (2017) Estimated prevalence of multiple sclerosis in Italy in 2015. Neurol Sci 38(3):473–479. https://doi.org/10.1007/s10072-016-2801-9CrossRefPubMed

20.

World Health Organization (2016) Global report on diabetes. https://www.who.int/publications/i/item/9789241565257. Accessed 30 Dec 2021

21.

Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Park Dis 8(s1):S3–S8. https://doi.org/10.3233/JPD-181474CrossRef

22.

Tolosa E, Wenning G, Poewe W (2006) The diagnosis of Parkinson’s disease. Lancet Neurol 5(1):75–86. https://doi.org/10.1016/S1474-4422(05)70285-4CrossRefPubMed

23.

Eurostat. Sales of pesticides in the EU. 2020 https://ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200603-1. Accessed 30 Dec 2021

24.

ISPRA. Rapporto nazionale pesticidi nelle acque-dati 2015–2016. Edizione 2018

25.

Lucchini RG, Guazzetti S, Renzetti S, et al (2020) Metal Exposure and SNCA rs356219 Polymorphism associated with Parkinson disease and Parkinsonism. Front Neurol. Dec 9;11:556337. https://doi.org/10.3389/fneur.2020.556337

26.

Fleury V, Himsl R, Joost S et al (2021) Geospatial analysis of individual-based Parkinson’s disease data supports a link with air pollution: a case-control study. Parkinsonism Relat Disord 83:41–48. https://doi.org/10.1016/j.parkreldis.2020.12.013CrossRefPubMed

27.

Fedeli U, Schievano E (2017) Increase in Parkinson’s disease-related mortality among males in Northern Italy. Parkinsonism Relat Disord 40:47–50. https://doi.org/10.1016/j.parkreldis.2017.04.008CrossRefPubMed

28.

Bezzini D, Kundisova L, Gori F et al (2020) Mortality trend for multiple sclerosis in Italy during the period 1980–2015. Mult Scler Relat Disord 44:102240. https://doi.org/10.1016/j.msard.2020.102240CrossRefPubMed

29.

Cislaghi C, Costa G, Rosano A. (2016) Una strage o solo un dato statistico? Il surplus di decessi nel 2015 [A mass murder or mere statistical data? The 2015 surplus of deaths]. Epidemiol Prev. 40(1):9–11. Italian. https://doi.org/10.19191/EP16.1.P009.005

30.

Désesquelles A, Demuru E, Salvatore MA et al (2014) Mortality from Alzheimer’s disease, Parkinson’s disease, and dementias in France and Italy: a comparison using the multiple cause-of-death approach. J Aging Health 26(2):283–315. https://doi.org/10.1177/0898264313514443CrossRefPubMed

31.

Goldacre MJ, Duncan M, Griffith M et al (2010) Trends in death certification for multiple sclerosis, motor neuron disease, Parkinson’s disease and epilepsy in English populations 1979–2006. J Neurol 257(5):706–715. https://doi.org/10.1007/s00415-009-5392-zCrossRefPubMed

32.

Black WC, Haggstrom DA, Welch HG (2002) All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94(3):167–173. https://doi.org/10.1093/jnci/94.3.167CrossRefPubMed

33.

ISTAT, guida alla lettura, page 1 https://www.istat.it/it/files//2011/02/Guida-alla-lettura1.pdf. Accessed 30 Dec 2021

34.

Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829. https://doi.org/10.1016/S1474-4422(07)70218-1CrossRefPubMed

35.

FDA. Pergolide (marketed as Permax) Information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/pergolide-marketed-permax-information. Accessed 30 Dec 2021

36.

Perez-Lloret S, Rey MV, Crispo J et al (2014) Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf 13(3):351–360. https://doi.org/10.1517/14740338.2014.888057CrossRefPubMed

37.

FDA Drug Safety Communication: Ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-parkinsons-drug-mirapex-pramipexole-and-possible. Accessed 30 Dec 2021

38.

Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson’s disease: a systematic review of observational studies. CNS Drugs 29(12):985–998. https://doi.org/10.1007/s40263-015-0293-4CrossRefPubMed

39.

Stowe RL, Ives NJ, Clarke C, et al (2008) Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2:CD006564. https://doi.org/10.1002/14651858.CD006564.pub2

40.

Caslake R, Macleod A, Ives N, Stowe R, Counsell C (2009) Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson’s disease. Cochrane Database Syst Rev 4:CD006661. https://doi.org/10.1002/14651858.CD006661.pub2

41.

Ulivelli M, Rossi S, Lombardi C et al (2002) Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology 58:462–465. https://doi.org/10.1212/wnl.58.3.462CrossRefPubMed

42.

Verhaeverbeke I, Mets T (1997) Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf 17(2):105–118. https://doi.org/10.2165/00002018-199717020-00003CrossRefPubMed

43.

Richard IH, Kurlan R, Tanner C et al (1997) Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson’s disease. Neurology 48:1070–1077. https://doi.org/10.1212/wnl.48.4.1070CrossRefPubMed

44.

Zemrak WR, Kenna GA (2008) Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 65(11):1029–1038. https://doi.org/10.2146/ajhp070279CrossRefPubMed

45.

Artusi CA, Lopiano L, Morgante F (2020) Deep brain stimulation selection criteria for Parkinson’s disease: time to go beyond CAPSIT-PD. J Clin Med 9:3931. https://doi.org/10.3390/jcm9123931CrossRefPubMedCentral

46.

Rocha AL, Oliveira A, Sousa C et al (2021) Long term mortality of patients with Parkinson’s disease treated with deep brain stimulation in a reference center. Clin Neurol Neurosurg 202:106486. https://doi.org/10.1016/j.clineuro.2021.106486CrossRefPubMed

47.

Artusi CA, Balestrino R, Imbalzano G et al (2020) Beyond 10 years of levodopa intestinal infusion experience: analysis of mortality and its predictors. Parkinsonism Relat Disord 76:98–103. https://doi.org/10.1016/j.parkreldis.2019.10.004CrossRefPubMed

48.

Crispo JAG, Lam M, Le B et al (2021) Survival and health care use after deep brain stimulation for Parkinson’s disease. Can J Neurol Sci 48(3):372–382. https://doi.org/10.1017/cjn.2020.187CrossRefPubMed

49.

Del Prete E, Francesconi A, Palermo G et al (2021) Prevalence and impact of COVID-19 in Parkinson’s disease: evidence from a multi-center survey in Tuscany region. J Neurol 268(4):1179–1187. https://doi.org/10.1007/s00415-020-10002-6CrossRefPubMed

Title: Mortality of Parkinson’s disease in Italy from 1980 to 2015
Authors: Monica Ulivelli
Daiana Bezzini
Lucia Kundisova
Ilaria Grazi
Mario Alberto Battaglia
Nicola Nante
Simone Rossi
Publication date: 01-06-2022
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Levodopa
Dopamine Agonist
Published in: Neurological Sciences / Issue 6/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05854-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Mortality of Parkinson’s disease in Italy from 1980 to 2015

Abstract

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2022

Central nervous system adverse events after ChAdOx1 vaccination

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

Neurotrauma in the Syrian War: analysis of 41,143 cases from July 2013–July 2015

Efficacy and safety of intravenous high-dose immunoglobulin in treatment of the severe form of Japanese encephalitis

Genetic screening in patients of Meige syndrome and blepharospasm

Task-switching abilities in episodic and chronic migraine